Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:43:24.453Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:43:24.453Z.
Quote observation: 2026-10-06T16:40:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
FORWARD PE RATIO
N/A
Latigo Biotherapeutics Inc.
Market Cap
$1.00B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Latigo Biotherapeutics Inc. (LTGO) | $1.00B | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $997.66M | N/A |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $989.59M | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $986.75M | 35.52 |
| Pacira BioSciences, Inc. (PCRX)vs › | $984.60M | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $984.28M | N/A |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.03B | 16.66 |
| Immatics N.V. (IMTX)vs › | $1.04B | N/A |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.04B | 5.47 |
| Janux Therapeutics, Inc. (JANX)vs › | $1.04B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
